^
No biomarker
Bladder Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
Bladder Cancer
EP
Sensitive: A2 - Guideline
PD-L1 expression
Bladder Cancer
atezolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
carboplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
enfortumab vedotin
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
gemcitabine + ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
paclitaxel + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
cisplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
avelumab
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
sacituzumab govitecan-hziy
Sensitive: A2 - Guideline
No biomarker
Bladder Cancer
inbakicept
Sensitive: B - Late Trials
PD-L1 expression
Bladder Cancer
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
Bladder Cancer
durvalumab
Sensitive: C1 - Off-label
TMB-H
Bladder Cancer
pembrolizumab
Sensitive: C1 - Off-label
PD-1 expression
Bladder Cancer
cisplatin
Sensitive: C2 – Inclusion Criteria
FGFR3 mutation
Bladder Cancer
infigratinib
Sensitive: C2 – Inclusion Criteria
FGFR1 amplification
Bladder Cancer
infigratinib
Sensitive: C2 – Inclusion Criteria
TET1 mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
BIRC5 expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
12-CK gene signature
Bladder Cancer
atezolizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
RB1 mutation + PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
DDR + PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
RB1 mutation
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
PBRM1 mutation
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
SBS5 signature
Bladder Cancer
cisplatin
Sensitive: C3 – Early Trials
BRCA2 mutation
Bladder Cancer
cisplatin
Sensitive: C3 – Early Trials
TMB-H
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
HER-2 amplification
Bladder Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
PBRM1 mutation
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
NOTCH1 mutation + TMB-L + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
ELF3 mutation + TMB-L + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
ELF3 mutation + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
NOTCH1 mutation + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
PIK3CA mutation + MSI-L/dMMR
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
PD-L1 overexpression
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
IFNG positive signature
Bladder Cancer
durvalumab
Sensitive: C3 – Early Trials
PTEN expression
Bladder Cancer
everolimus
Sensitive: C3 – Early Trials
HER-2 overexpression
Bladder Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
IFNA1 expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
IFNG expression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
TSC1 mutation
Bladder Cancer
everolimus
Sensitive: C3 – Early Trials
PD-L1 expression
Bladder Cancer
nivolumab + BMS-986205
Sensitive: C3 – Early Trials
HER-2 mutation + TMB-H
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
ERBB3 mutation + TMB-H
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
PCSK9 underexpression
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
LRP1B mutation + TMB-H
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
DDR
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
CXCL13 expression
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
RAD52 underexpression
Bladder Cancer
cisplatin
Resistant: C3 – Early Trials
RNF43 mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
KMT2C mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1-H
Bladder Cancer
Immunotherapy
Resistant: C3 – Early Trials
TDO2 overexpression
Bladder Cancer
cetuximab
Resistant: C3 – Early Trials
TLR4-L
Bladder Cancer
gemcitabine
Sensitive: C3 – Early Trials
ARID1A mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PIK3CA M1043I
Bladder Cancer
everolimus
Sensitive: C4 – Case Studies
MSH4 L359I
Bladder Cancer
atezolizumab
Sensitive: C4 – Case Studies
TSC1 1907_1908del
Bladder Cancer
everolimus
Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion
Bladder Cancer
erdafitinib
Sensitive: C4 – Case Studies
ERCC2 E606Q
Bladder Cancer
cisplatin + gemcitabine
Sensitive: C4 – Case Studies
ERCC2 E606Q
Bladder Cancer
carboplatin + gemcitabine
Sensitive: C4 – Case Studies
PD-L1 expression + TMB-H
Bladder Cancer
pembrolizumab
Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion
Bladder Cancer
TAS 120
Sensitive: D – Preclinical
FGFR3 overexpression
Bladder Cancer
TAS 120
Sensitive: D – Preclinical
ERBB3 expression
Bladder Cancer
lapatinib
Resistant: D – Preclinical
ARID1A mutation
Bladder Cancer
GSK2816126
Sensitive: D – Preclinical
HRAS mutation
Bladder Cancer
FL118
Sensitive: D – Preclinical
KRAS mutation
Bladder Cancer
FL118
Sensitive: D – Preclinical
FGFR3 S249C
Bladder Cancer
ponatinib
Sensitive: D – Preclinical
FGFR1 overexpression
Bladder Cancer
TKI258
Sensitive: D – Preclinical
FGFR1 overexpression
Bladder Cancer
PD 0173074
Sensitive: D – Preclinical
PPARG positive
Bladder Cancer
rosiglitazone
Sensitive: D – Preclinical
FGFR3-TACC3 fusion
Bladder Cancer
MPT0L145
Sensitive: D – Preclinical
LYPD3 expression
Bladder Cancer
BAY1129980
Sensitive: D – Preclinical
MTAP deletion
Bladder Cancer
IDE397
Sensitive: D – Preclinical
HYAL4 V1
Bladder Cancer
gemcitabine
Resistant: D – Preclinical
HYAL4 V1
Bladder Cancer
gemcitabine + EPI01
Sensitive: D – Preclinical
WDR5 overexpression
Bladder Cancer
OICR-9429
Resistant: D – Preclinical